Bank of New York Mellon’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $380M | Sell |
1,578,013
-101,358
| -6% | -$22.2M | 0.06% | 268 |
|
|
2026
Q1 | $317M | Buy |
1,679,371
+517,514
| +45% | +$90.4M | 0.06% | 282 |
|
|
2025
Q4 | $198M | Buy |
1,161,857
+715,361
| +160% | +$110M | 0.03% | 382 |
|
|
2025
Q3 | $58.8M | Sell |
446,496
-21,990
| -5% | -$2.64M | 0.01% | 921 |
|
|
2025
Q2 | $49.7M | Sell |
468,486
-12,900
| -3% | -$1.4M | 0.01% | 1003 |
|
|
2025
Q1 | $59.8M | Buy |
481,386
+3,635
| +0.8% | +$474K | 0.01% | 853 |
|
|
2024
Q4 | $58.8M | Buy |
477,751
+24,481
| +5% | +$2.89M | 0.01% | 904 |
|
|
2024
Q3 | $50.5M | Sell |
453,270
-59,543
| -12% | -$6.52M | 0.01% | 1028 |
|
|
2024
Q2 | $54.7M | Sell |
512,813
-47,982
| -9% | -$5.28M | 0.01% | 970 |
|
|
2024
Q1 | $67.5M | Sell |
560,795
-19,229
| -3% | -$2.36M | 0.01% | 871 |
|
|
2023
Q4 | $71.3M | Sell |
580,024
-39,875
| -6% | -$4.98M | 0.01% | 828 |
|
|
2023
Q3 | $80.2M | Sell |
619,899
-1,978
| -0.3% | -$264K | 0.02% | 732 |
|
|
2023
Q2 | $77.1M | Sell |
621,877
-10,110
| -2% | -$1.36M | 0.02% | 762 |
|
|
2023
Q1 | $92.5M | Sell |
631,987
-18,143
| -3% | -$2.68M | 0.02% | 653 |
|
|
2022
Q4 | $104M | Buy |
650,130
+203
| +0% | +$29.8K | 0.02% | 595 |
|
|
2022
Q3 | $86.6M | Buy |
649,927
+47,501
| +8% | +$7.22M | 0.02% | 648 |
|
|
2022
Q2 | $94M | Buy |
602,426
+23,253
| +4% | +$3.58M | 0.02% | 622 |
|
|
2022
Q1 | $90.2M | Sell |
579,173
-12,607
| -2% | -$1.83M | 0.02% | 731 |
|
|
2021
Q4 | $75.4M | Sell |
591,780
-10,862
| -2% | -$1.43M | 0.01% | 872 |
|
|
2021
Q3 | $78.5M | Sell |
602,642
-20,569
| -3% | -$3.11M | 0.02% | 820 |
|
|
2021
Q2 | $111M | Buy |
623,211
+22,553
| +4% | +$3.91M | 0.02% | 654 |
|
|
2021
Q1 | $98.7M | Buy |
600,658
+10,632
| +2% | +$1.75M | 0.02% | 705 |
|
|
2020
Q4 | $97.4M | Sell |
590,026
-3,636
| -0.6% | -$542K | 0.02% | 667 |
|
|
2020
Q3 | $84.7M | Buy |
593,662
+298,814
| +101% | +$37M | 0.02% | 643 |
|
|
2020
Q2 | $32.5M | Sell |
294,848
-18,694
| -6% | -$2.07M | 0.01% | 1149 |
|
|
2020
Q1 | $31.3M | Sell |
313,542
-411,563
| -57% | -$53.2M | 0.01% | 1021 |
|
|
2019
Q4 | $108M | Sell |
725,105
-42,201
| -5% | -$5.74M | 0.03% | 567 |
|
|
2019
Q3 | $98.3M | Sell |
767,306
-188,898
| -20% | -$25.3M | 0.03% | 601 |
|
|
2019
Q2 | $136M | Sell |
956,204
-328,606
| -26% | -$44.2M | 0.04% | 460 |
|
|
2019
Q1 | $184M | Sell |
1,284,810
-160,671
| -11% | -$21M | 0.05% | 352 |
|
|
2018
Q4 | $179M | Sell |
1,445,481
-244,904
| -14% | -$36.3M | 0.06% | 320 |
|
|
2018
Q3 | $284M | Buy |
1,690,385
+207,954
| +14% | +$35.8M | 0.07% | 257 |
|
|
2018
Q2 | $255M | Sell |
1,482,431
-142,460
| -9% | -$23.3M | 0.07% | 278 |
|
|
2018
Q1 | $245M | Sell |
1,624,891
-135,656
| -8% | -$19.9M | 0.07% | 293 |
|
|
2017
Q4 | $237M | Buy |
1,760,547
+274,121
| +18% | +$38M | 0.06% | 319 |
|
|
2017
Q3 | $217M | Buy |
1,486,426
+105,838
| +8% | +$16M | 0.06% | 336 |
|
|
2017
Q2 | $215M | Sell |
1,380,588
-67,172
| -5% | -$10.3M | 0.06% | 333 |
|
|
2017
Q1 | $210M | Buy |
1,447,760
+44,973
| +3% | +$5.86M | 0.06% | 344 |
|
|
2016
Q4 | $153M | Buy |
1,402,787
+236,568
| +20% | +$26.3M | 0.04% | 422 |
|
|
2016
Q3 | $142M | Sell |
1,166,219
-66,834
| -5% | -$9.01M | 0.04% | 414 |
|
|
2016
Q2 | $174M | Buy |
1,233,053
+49,967
| +4% | +$7.37M | 0.05% | 356 |
|
|
2016
Q1 | $154M | Buy |
1,183,086
+86,219
| +8% | +$10.7M | 0.05% | 387 |
|
|
2015
Q4 | $154M | Buy |
1,096,867
+70,119
| +7% | +$9.72M | 0.05% | 385 |
|
|
2015
Q3 | $136M | Sell |
1,026,748
-87,618
| -8% | -$15.1M | 0.04% | 427 |
|
|
2015
Q2 | $196M | Sell |
1,114,366
-33,295
| -3% | -$5.98M | 0.05% | 365 |
|
|
2015
Q1 | $198M | Buy |
1,147,661
+568,476
| +98% | +$97.6M | 0.05% | 381 |
|
|
2014
Q4 | $94.8M | Buy |
579,185
+65,796
| +13% | +$10.9M | 0.02% | 613 |
|
|
2014
Q3 | $82.4M | Buy |
513,389
+261,281
| +104% | +$40.2M | 0.02% | 647 |
|
|
2014
Q2 | $37.1M | Sell |
252,108
-17,113
| -6% | -$2.37M | 0.01% | 1075 |
|
|
2014
Q1 | $37.3M | Sell |
269,221
-349,858
| -57% | -$52.7M | 0.01% | 1076 |
|
|
2013
Q4 | $78.4M | Sell |
619,079
-78,810
| -11% | -$8.16M | 0.02% | 666 |
|
|
2013
Q3 | $64.2M | Sell |
697,889
-51,335
| -7% | -$4.14M | 0.02% | 733 |
|
|
2013
Q2 | $51.5M | Buy |
+749,224
| New | +$45.8M | 0.02% | 812 |
|
Other funds holding JAZZ
Bank of New York Mellon's JAZZ Position: Q2 2026 in Review
Bank of New York Mellon reduced its Jazz Pharmaceuticals (JAZZ) stake by 6% in Q2 2026, selling an estimated $22.2M and leaving 1,578,013 shares worth $380M. The position accounts for 0.06% of the portfolio, ranked #268.
Bank of New York Mellon first reported a position in JAZZ in Q2 2013 and has held it in 53 quarters since. 420 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- Bank of New York Mellon held 1,578,013 shares of Jazz Pharmaceuticals worth $380M as of Q2 2026.
- Bank of New York Mellon sold 101,358 Jazz Pharmaceuticals shares in Q2 2026, an estimated $22.2M.
- Jazz Pharmaceuticals made up 0.06% of Bank of New York Mellon's portfolio in Q2 2026, its #268 holding.
- Bank of New York Mellon first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- 420 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.